Could cause temporary or reversible harm; serious harm is unlikely.
Failed Impurities/Degradation Specifications
| Brand name | CEFIXIME |
| Generic name | CEFIXIME |
| Active ingredient(s) | CEFIXIME |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 |
| NDC | 68180-405-01 |
| Full product label | Cefixime for Oral Suspension 100mg/5mL, 50 mL bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by:Lupin Limited, Mandideep 462 046 INDIA, NDC 68180-405-01 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Nationwide in the USA |
| Quantity | 4,608 Bottles |
| Recall initiated | 2024-01-03 |
| Report date | 2024-02-07 |
| Recall completed | 2024-12-27 |
| Recall number | D-0274-2024 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗